Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by alleyesonmeon Mar 31, 2024 2:59pm
76 Views
Post# 35961808

RE:Unsolicited takeover bid…

RE:Unsolicited takeover bid…The value would be very clear for a pharmaceutical corporation considering the dronabinol API and producer shortage, the move towards more shelf stable cheaper, natural cannabinoids when compared to the synthetic competitors, this also applies to CBD and the inevitability of the epidiolex generic and the demand that comes with it for CBD api, who else is licensed and capable of meeting such demand...let's not forget GW announced expansion for epidiolex production at an estimated 100m...despite patents for dronabinol/marinol/sativex, generics have been approved, same will happen with epidiolex only epidiolex revenue is 4x dronabinol...iv said this before...if jazz wants to protect its billion dollar baby they could add years to the monopoly and add capacity for North America by purchasing MPL...are they the bidder?...look at the landscape, MPL is years ahead..unsolicited takeover bid in progress IMO....considering the developments recently the time for this to happen is now. 
<< Previous
Bullboard Posts
Next >>